| __timestamp | Bristol-Myers Squibb Company | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 2917513 |
| Thursday, January 1, 2015 | 5001000000 | 7878291 |
| Friday, January 1, 2016 | 5002000000 | 8366794 |
| Sunday, January 1, 2017 | 4849000000 | 6610381 |
| Monday, January 1, 2018 | 4551000000 | 6556000 |
| Tuesday, January 1, 2019 | 4871000000 | 6930000 |
| Wednesday, January 1, 2020 | 7661000000 | 8758000 |
| Friday, January 1, 2021 | 7690000000 | 10806000 |
| Saturday, January 1, 2022 | 7814000000 | 9844000 |
| Sunday, January 1, 2023 | 7772000000 | 13481000 |
| Monday, January 1, 2024 | 8414000000 |
Infusing magic into the data realm
In the world of pharmaceuticals, the financial strategies of companies can vary dramatically. Bristol-Myers Squibb Company, a titan in the industry, has consistently demonstrated robust spending on Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, their SG&A expenses have shown a steady increase, peaking in 2022 with a 37% rise from 2014. This reflects their aggressive market strategies and expansive operational scale.
In stark contrast, Soleno Therapeutics, Inc., a smaller player, has maintained a more conservative approach. Their SG&A expenses have grown by approximately 362% over the same period, yet remain a fraction of Bristol-Myers Squibb's. This highlights the differing scales and strategies between large and small pharmaceutical companies.
These trends underscore the diverse financial landscapes within the pharmaceutical sector, offering insights into how companies allocate resources to maintain competitiveness and drive growth.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Soleno Therapeutics, Inc.
Bristol-Myers Squibb Company vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Viking Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Bristol-Myers Squibb Company vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for argenx SE and Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Alpine Immune Sciences, Inc. and Soleno Therapeutics, Inc.
PTC Therapeutics, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for MorphoSys AG and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Soleno Therapeutics, Inc. or Iovance Biotherapeutics, Inc.